HighMark Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.16K | Buy |
57
+18
| +46% | +$2.26K | ﹤0.01% | 352 |
|
|
2025
Q1 | $4.31K | Hold |
39
| – | – | ﹤0.01% | 384 |
|
|
2024
Q4 | $5.32K | Buy |
39
+14
| +56% | +$1.91K | ﹤0.01% | 374 |
|
|
2024
Q3 | $2.88K | Sell |
25
-15
| -38% | -$1.73K | ﹤0.01% | 453 |
|
|
2024
Q2 | $5.51K | Sell |
40
-20
| -33% | -$2.75K | ﹤0.01% | 375 |
|
|
2024
Q1 | $8.28K | Buy |
60
+3
| +5% | +$414 | 0.01% | 312 |
|
|
2023
Q4 | $7.51K | Hold |
57
| – | – | 0.01% | 309 |
|
|
2023
Q3 | $6.41K | Hold |
57
| – | – | 0.01% | 319 |
|
|
2023
Q2 | $5.38K | Buy |
57
+2
| +4% | +$189 | ﹤0.01% | 340 |
|
|
2023
Q1 | $5.57K | Hold |
55
| – | – | ﹤0.01% | 377 |
|
|
2022
Q4 | $6.57K | Sell |
55
-6
| -10% | -$717 | 0.01% | 307 |
|
|
2022
Q3 | $6K | Hold |
61
| – | – | 0.01% | 310 |
|
|
2022
Q2 | $6K | Sell |
61
-4
| -6% | -$393 | ﹤0.01% | 323 |
|
|
2022
Q1 | $6K | Hold |
65
| – | – | ﹤0.01% | 341 |
|
|
2021
Q4 | $6K | Hold |
65
| – | – | ﹤0.01% | 345 |
|
|
2021
Q3 | $6K | Sell |
65
-3
| -4% | -$277 | ﹤0.01% | 327 |
|
|
2021
Q2 | $7K | Sell |
68
-12
| -15% | -$1.24K | 0.01% | 313 |
|
|
2021
Q1 | $8K | Buy |
80
+51
| +176% | +$5.1K | 0.01% | 275 |
|
|
2020
Q4 | $3K | Buy |
+29
| New | +$3K | ﹤0.01% | 386 |
|